Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway

Journal of Translational Medicine

Meeting Report

Anne-Lise Børresen-Dale¹  Hans E. Krokan²  Oluf D. Røe³  Mogens Vyberg⁴  Karina Standahl Olsen⁵  Ioannis Tsamardinos⁶  Pål Sætrom⁷  Nagahiro Minato⁸  Vassilis Georgoulias⁹  Jianwei Zhou^1,10  Dana W.T. Tsui^1,11  Robert A. Anders^1,12  Vassiliki Papadimitrakopoulou^1,13  Katalin Dobra^1,14  Michaela B. Kirschner^1,15  Ana I. Robles^1,16  Boye Schnack Nielsen^1,17  Jenette Creaney^1,18 

[1] Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway;Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway;Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway;Cancer Clinic, Department of SurgeryLevanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway;Department of Clinical Medicine, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark;Department of Clinical Medicine, Institute of Pathology, Aalborg University Hospital, Aalborg University, Aalborg, Denmark;Department of Community Medicine, UiT The Artic University of Norway, Tromsø, Norway;Department of Computer Science, University of Crete, Heraklion, Greece;Department of Computer and Information Science, NTNU, Trondheim, Norway;Department of Immunology and Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;Department of Medical Oncology, School of MedicineUniversity of Crete, Heraklion, Greece;Department of Molecular Cell Biology & Toxicology, Cancer Center School of Public Health, Nanjing Medical University, Nanjing, People’s Republic of China;Department of Pathology and Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA;Department of Pathology, Johns Hopkins University, Baltimore, USA;Department of Thoracic/Head and Neck Medical Oncology, MD Anderson, Houston, USA;Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden;Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland;Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, USA;Molecular Histology Bioneer A/S, Hørsholm, Denmark;National Centre for Asbestos Related Disease, University of Western Australia, Perth, Australia;

关键词: Bioinformatics;    Circulating biomarkers;    Circulating tumor cells;    DNA repair;    Early detection;    Early diagnosis;   

DOI  :  10.1186/s12967-016-1059-6

 received in 2016-09-01, accepted in 2016-10-10,  发布年份 2016

来源: Springer

【 摘 要 】

The goal of biomarker research is to identify clinically valid markers. Despite decades of research there has been disappointingly few molecules or techniques that are in use today. The “1st International NTNU Symposium on Current and Future Clinical Biomarkers of Cancer: Innovation and Implementation”, was held June 16th and 17th 2016, at the Knowledge Center of the St. Olavs Hospital in Trondheim, Norway, under the auspices of the Norwegian University of Science and Technology (NTNU) and the HUNT biobank and research center. The Symposium attracted approximately 100 attendees and invited speakers from 12 countries and 4 continents. In this Symposium original research and overviews on diagnostic, predictive and prognostic cancer biomarkers in serum, plasma, urine, pleural fluid and tumor, circulating tumor cells and bioinformatics as well as how to implement biomarkers in clinical trials were presented. Senior researchers and young investigators presented, reviewed and vividly discussed important new developments in the field of clinical biomarkers of cancer, with the goal of accelerating biomarker research and implementation. The excerpts of this symposium aim to give a cutting-edge overview and insight on some highly important aspects of clinical cancer biomarkers to-date to connect molecular innovation with clinical implementation to eventually improve patient care.

【 授权许可】

CC BY   
© The Author(s) 2016